Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Blanes M.; Lorenzo J. I.; Ribas P.; Jimenez A.; Gonzalez J. D.; Cejalvo M. J.; Solano C.; Alegre A.; de la Rubia Javier

首页> 外文期刊>Annals of hematology >Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

【24h】

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

机译：静脉内伯鲁兰加上梅酚与Melphalan单独用作多发性骨髓瘤患者的调理方案

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of hematology》 |2019年第8期|共3页
作者
Blanes M.; Lorenzo J. I.; Ribas P.; Jimenez A.; Gonzalez J. D.; Cejalvo M. J.; Solano C.; Alegre A.; de la Rubia Javier;
展开▼
作者单位

Univ Hosp Gen Elda Hematol Serv Alicante Spain;

Univ Hosp La Fe Hematol Serv Valencia Spain;

Univ Hosp Doctor Peset Hematol Serv Valencia Spain;

Univ Hosp 12 Octubre Hematol Serv Madrid Spain;

Univ Hosp Insular Canarias Hematol Serv Las Palmas Gran Canaria Spain;

Univ Hosp Doctor Peset Hematol Serv Valencia Spain;

Univ Hosp Clin Hematol Serv Valencia Spain;

Univ Hosp La Princesa Hematol Serv Madrid Spain;

Univ Hosp Doctor Peset Hematol Serv Valencia Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词
入库时间 2022-08-20 01:03:13

相似文献

外文文献
中文文献
专利

1. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma [J] . Blanes M., Lorenzo J. I., Ribas P., Annals of hematology . 2019,第8期

机译：静脉内伯鲁兰加上梅酚与Melphalan单独用作多发性骨髓瘤患者的调理方案
2. Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma [J] . Songyi Park, Dong-Yeop Shin, Junshik Hong, Therapeutic advances in hematology. . 2021,第a期

机译：Busulfan Plus Melphalan与Melphalan独自调节方案基于Bortezomib基于Triplet诱导化疗的新诊断患者的多重骨髓瘤
3. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma [J] . Rodriguez Tulio E., Hari Parameswaran, Stiff Patrick J., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第8期

机译：白消安，美法仑和硼替佐米与高剂量美法仑作为多发性骨髓瘤自体造血干细胞移植的条件治疗方案
4. Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies [C] . G. Jackson, C. Richardson, G. Morgan, European Haematology Association . 2002

机译：Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理（RIC）治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study [O] . Juan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, 2010

机译：PETHEMA / GEM2000研究中白消安12 mg / kg加美法仑140 mg / m2对比美法仑200 mg / m2作为新诊断的多发性骨髓瘤患者自体移植的条件疗法
7. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach [O] . Blanes, Margarita, Lahuerta, Juan José, Bladé, Joan, 2016

机译：静脉使用白消安和美法仑作为新诊断多发性骨髓瘤患者自体干细胞移植的条件疗法：与仅美法仑的治疗方案相匹配的比较

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

著录项

相似文献

相关主题

期刊订阅